The SPIRIT Initiative: Defining standard protocol items

Similar documents
The QUOROM Statement: revised recommendations for improving the quality of reports of systematic reviews

The influence of CONSORT on the quality of reports of RCTs: An updated review. Thanks to MRC (UK), and CIHR (Canada) for funding support

Dissemination experiences from CONSORT and other reporting guidelines

Mitigating Reporting Bias in Observational Studies Using Covariate Balancing Methods

Title 1 Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym

CONSORT extension. CONSORT for Non-pharmacologic interventions. Isabelle Boutron

Statistical Analysis Plans

CONSORT 2010 checklist of information to include when reporting a randomised trial*

ARCHE Risk of Bias (ROB) Guidelines

Guidelines for Reporting Non-Randomised Studies

Web appendix (published as supplied by the authors)

Cochrane Bone, Joint & Muscle Trauma Group How To Write A Protocol

PROTOCOL: Reporting Guidelines Systematic Review 1. Dr. David Moher

Webinar 3 Systematic Literature Review: What you Need to Know

Assessing the risk of outcome reporting bias in systematic reviews

Garbage in - garbage out? Impact of poor reporting on the development of systematic reviews

Reporting guidelines

Introduction to systematic reviews/metaanalysis

Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement

Applying the Risk of Bias Tool in a Systematic Review of Combination Long-Acting Beta-Agonists and Inhaled Corticosteroids for Persistent Asthma

Systematic Reviews and Meta- Analysis in Kidney Transplantation

School of Dentistry. What is a systematic review?

Learning from Systematic Review and Meta analysis

Improving reporting for observational studies: STROBE statement

Results. NeuRA Worldwide incidence April 2016

Controlled Trials. Spyros Kitsiou, PhD

The Cochrane Skin Group - Core Outcome Set Initiative to develop core outcome sets across the whole of dermatology

Uses and misuses of the STROBE statement: bibliographic study

Systematic Reviews. Simon Gates 8 March 2007

Systematic reviews and meta-analyses are essential tools. Academia and Clinic

The importance of good reporting of medical research. Doug Altman. Centre for Statistics in Medicine University of Oxford

From protocol to publication: ensuring quality in the reporting of continence research Workshop 20 Monday, August 23rd 2010, 14:00 17:00

REVIEW. What is the quality of reporting in weight loss intervention studies? A systematic review of randomized controlled trials

N of 1 trials: planning, conduct, and evaluation

Traumatic brain injury

Reporting randomised trials of social and psychological interventions: the CONSORT- SPI 2018 Extension

Models for potentially biased evidence in meta-analysis using empirically based priors

What is the Cochrane Collaboration? What is a systematic review?

RARE-Bestpractices Conference

EQUATOR Network: promises and results of reporting guidelines

Methods in Research on Research. The Peer Review Process. Why Evidence Based Practices Are Needed?

Reporting of Randomized Controlled Trials in Hodgkin Lymphoma in Biomedical Journals

Information Sharing Session on Rapid Review Initiatives. Chantelle Garritty Ottawa Methods Centre, Ottawa Hospital Research Institute (OHRI)

Cochrane Breast Cancer Group

The Cochrane Collaboration, the US Cochrane Center, and The Cochrane Library

Results. NeuRA Treatments for internalised stigma December 2017

Meta-analysis of safety thoughts from CIOMS X

Eldridge, SM, Chan, CL, Campbell, MJ, Bond, CM, Hopewell, S, Thabane, L and Lancaster, GA

Other potential bias. Isabelle Boutron French Cochrane Centre Bias Method Group University Paris Descartes

Component of CPG development ILAE Recommendation Document Identifying topic and developing clinical. S3 research question

Problem solving therapy

BIASES IN CONTROLLED CLINICAL TRIALS SILVIO GARATTINI. Ranica 23 Maggio 2007

Guidance on specifying the target difference ( effect size ) for a RCT

Supplementary Online Content

Zhengtao Liu 1,2,3*, Shuping Que 4*, Lin Zhou 1,2,3 Author affiliation:

Progress from the Patient-Centered Outcomes Research Institute (PCORI)

Results. NeuRA Hypnosis June 2016

Randomized Controlled Trial

Maxing out on quality appraisal of your research: Avoiding common pitfalls. Policy influenced by study quality

What do letters to the editor publish about randomized controlled trials? A cross-sectional study

Journal of Clinical Epidemiology 62 (2009) e1ee34. Accepted 22 June 2009

Predictors of publication: characteristics of submitted manuscripts associated with acceptance at major biomedical journals

research methods & reporting

Systematic reviews and meta-analyses of observational studies (MOOSE): Checklist.

Accepted refereed manuscript of:

Animal-assisted therapy

Distraction techniques

CONSORT 2010 Statement Annals Internal Medicine, 24 March History of CONSORT. CONSORT-Statement. Ji-Qian Fang. Inadequate reporting damages RCT

Critical Appraisal of a Meta-Analysis: Rosiglitazone and CV Death. Debra Moy Faculty of Pharmacy University of Toronto

Table S1- PRISMA 2009 Checklist

AXIS critical Appraisal of cross sectional Studies

cohort study case-control study cross-sectional study benefit transparency credibility randomized controlled trial: RCT critical assessment

Washington, DC, November 9, 2009 Institute of Medicine

Meta-Analyses: Considerations for Probiotics & Prebiotics Studies

Systematic reviews vs. rapid reviews: What s the difference?

Evidence Supporting the Recommendations. Implementation of the Guideline. Benefits/Harms of Implementing the Guideline Recommendations

PROSPERO International prospective register of systematic reviews

Many questions in medical research are investigated in

The Role and Importance of Clinical Trial Registries and Results Databases

Results. NeuRA Mindfulness and acceptance therapies August 2018

Standards for the reporting of new Cochrane Intervention Reviews

Epidemiology and Reporting Characteristics of Systematic Reviews

Appendices. Appendix A Search terms

Empirical evidence on sources of bias in randomised controlled trials: methods of and results from the BRANDO study

Reducing waste in research

Chairman, Department of Sports Rehabilitation, Shanghai University of Sport

Robert M. Jacobson, M.D. Department of Pediatric and Adolescent Medicine Mayo Clinic, Rochester, Minnesota

Assessment of Risk of Bias Among Pediatric Randomized Controlled Trials

Workshop: Cochrane Rehabilitation 05th May Trusted evidence. Informed decisions. Better health.

2. The effectiveness of combined androgen blockade versus monotherapy.

Quality of Reporting of Modern Randomized Controlled Trials in Medical Oncology: A Systematic Review

GRADE. Grading of Recommendations Assessment, Development and Evaluation. British Association of Dermatologists April 2018

University of Bristol - Explore Bristol Research

A Systematic Review of the Efficacy and Clinical Effectiveness of Group Analysis and Analytic/Dynamic Group Psychotherapy

Secular Changes in the Quality of Published Randomized Clinical Trials in Rheumatology

NeuRA Schizophrenia diagnosis May 2017

Why published medical research may not be good for your health

The EQUATOR Network: a global initiative to improve the quality of reporting research

Final Accreditation Report

CONSORT: missing missing data guidelines, the effects on HTA monograph reporting Yvonne Sylvestre

Transcription:

The SPIRIT Initiative: Defining standard protocol items October 11, 2012 An-Wen Chan, MD DPhil Women s College Hospital & Research Institute University of Toronto

Importance of trial protocols Trial registries Trialists Patients & Trial participants Journals Trial roadmap Scientific & ethics review Origin of subsequent reporting Transparency Funders Regulators/ Policymakers Healthcare providers Ethics boards

Protocols facilitate transparency Diabetes trial Drug intervention Protocol Primary outcome: % change in Hgb A1C Publication Primary outcome: % Withdrawal change in Hgb rate A1C P 0.05 P<0.05 Chan AW et al, JAMA 2004; CMAJ 2004

Current landscape of protocols Incomplete information Variable standards Variable format

Protocols lack important information Primary outcome analysis Allocation concealment Allocation Allocation concealment 59% Power calculation Handling of missing Blinding data 34% ndling of Primary protocol Primary outcomes deviations 25% Power Adjusted Power calculation analyses 40% Subgroup analyses Harms Harms reporting reporting system 41% 0% 20% 40% 60% 80% 100% % of protocols with inadequate information 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% Mhaskar R et al, J Clin Epid 2012; Chan AW et al, BMJ 2008, JAMA 2004; Scharf O, J Clin Oncol 2006; Pildal J, BMJ 2005; Hróbjartsson A et al, J Clin Epid 2009

Protocols lack important information Primary outcome analysis Primary Allocation 1º outcome concealment analysis 20% Handling Power of of missing calculation data Handling of missing data ndling Handling of protocol of deviations ndling of protocol deviations Adjusted Adjusted analyses analyses 47% 67% 77% Subgroup analyses 95% 0% 0% 20% 40% 60% 80% 100% % of protocols with inadequate information Chan AW et al, BMJ 2008; Al-Marzouki S et al, Lancet 2008

Objective To improve content and quality of clinical trial protocols through evidence-based guidance

Definition of protocol Pre-trial document submitted for ethics approval Background & objectives Population & interventions Methods & statistical analyses Ethical and administrative aspects Evolving document Transparent audit trail Related documents (SAP, contracts)

Methods Systematic reviews: Existing protocol guidelines Evidence for key protocol items Delphi consensus survey Consensus meetings SPIRIT 2012 Checklist Explanatory document

Systematic review of protocol guidelines 40 guidelines identified 7 specific to RCTs No formal consensus methods or systematic retrieval of evidence >380 protocol elements Most were found in only 1 guideline Tetzlaff J et al, Systematic Reviews 2012

Delphi consensus survey Preliminary checklist based on systematic review 3 survey rounds from Aug Nov 2007 96 participants from 17 countries Items rated from 1-10 Ratings and comments circulated in each round Median 8 Included Median 5 Excluded Tetzlaff J et al, Trials 2012

Consensus meetings (December 2007 and September 2009) 20 participants Trialists, methodologists, industry, ethicists, funders, journal editors Review of protocol items from Delphi survey

Systematic review of evidence 10725 citations screened (MEDLINE, EMBASE, Cochrane Methodology Register) 2433 articles reviewed 376 methodologic articles included

Evolution of SPIRIT Checklist Systematic review of protocol guidelines 59 items Delphi consensus survey 71 items Consensus meetings 33 items Systematic review of evidence

SPIRIT 2012 Checklist 33 items in five categories Administrative information Introduction Study methods Ethical considerations & dissemination Appendices Chan AW et al, Annals Intern Med [in press]

Schematic participant timeline Study period Pre-allocation Randomization Postallocation follow-up Close -out TIMEPOINT ENROLLMENT INTERVENTIONS ASSESSMENTS

Scope All clinical trials Minimum content Relevant information from contracts & operations manuals

SPIRIT Explanation & Elaboration Model example Rationale and explanation References to empirical evidence and further reading Chan AW et al, BMJ [in press]

Users Investigators Educators Protocol reviewers Funders Research ethics committees Journals

Relation to other guidance Declaration of Helsinki Good Clinical Practice CDISC Protocol Representation Group PRACTIHC (Pragmatic RCTs In Health Care)

Implementation strategy Dissemination Endorsement and enforcement Implementation tools Evaluation of impact

Conclusions Trial protocols are central to transparency, scientific validity, and ethical rigour SPIRIT checklist aims to improve protocol quality Impact requires broad adoption www.spirit-statement.org

Trialists/Methodologists/Statisticians An-Wen Chan (Chair), Univ of Toronto Jennifer Tetzlaff, University of Ottawa David Moher, University of Ottawa Doug Altman, University of Oxford Kay Dickersin, Johns Hopkins University Caroline Doré, UK MRC Peter Gøtzsche, Nordic Cochrane Centre Asbjørn Hŕobjartsson, Nordic Cochrane Wendy Parulekar, NCIC CTG Ken Schulz, Family Health International Andreas Laupacis, University of Toronto Industry Jesse Berlin, Johnson & Johnson Frank Rockhold, GSK Journal editors Trish Groves, BMJ Bill Summerskill, Lancet Drummond Rennie, JAMA Hal Sox, Annals of Internal Medicine Government funders Karmela Krleža-Jerić, Canadian Institutes of Health Research Ethicists Howard Mann, University of Utah Genevieve Dubois-Flynn, Canadian Institutes of Health Research